Expert Opinion on Pharmacotherapy

About the Journal

Journal cover

Editor-In-Chief: Dimitri Mikhailidis, Royal Free Hospital, UK

Commissioning Editor: Claire Attwood

Production Manager: Jonathan Collard

2012 ISI Impact Factor: 2.86


ISSN: 1465-6566 (print), 1744-7666 (electronic)

Early Online

Latest News

  • Melanoma treatment – BRAF or non-BRAF therapies? Chemical versus biological drugs? Find out more!

    April 17, 0014
    This month Expert Opinion have delved into the various treatments available for melanoma
  • What is FDA approved and what are the new therapeutic targets for treating SLE?

    April 9, 2022

    Look no further than these (some FREE) articles from Expert Opinion’s April issues!

  • Dimitri Mikhailidis chooses Evaluation of Alogliptin benzoate as April highlight!

    April 1, 2022
    Dimitri Mikhailidis Editor in Chief of Expert Opinion on Pharmacoherapy chooses Drug Evaluation on the recently approved Alogliptin benzoate for the treatment of type 2 diabetes as the Editors pick from the first half of our April content!
  • What is the best option for treatment of preterm labour?

    March 7, 2022
    Expert Opinion on Pharmacotherapy has recently published a review and an editorial trying to answer this question.
  • New topical treatments for psoriasis is our Editor’s pick of the month!

    February 21, 2022
    New topical treatments for psoriasis by Chiricozzi et al. is our pick of the Expert Opinion on Pharmacotherapy March issue from Editor-in-Chief Dimitri Mikhailidis (UCL, London). Read more here
  • Considering current options for treating pulmonary arterial hypertension

    February 21, 2022
    This month in Expert Opinion, treatments for pulmonary arterial hypertension are considered. We cover drugs that are established, recently approved and in phase III trials as well as evaluating the management of the condition in patients with congenital heart disease.
  • First half of the First-in-Class cross-series themed issue available now!

    February 17, 2022
    First-in-Class drugs and their novel mechanisms of action are the focus of the first Expert Opinion and Expert ReviewsCross-series themed issue. All articles will be published in their respective journals between January and April 2022 so half of them are already available!
  • Editor’s pick – the efficacy of sodium oxybate in treating alcohol dependence

    January 27, 2022
    Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has chosen the drug evaluation: Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention by Skala et al., as the Editor’s pick for the February issues.
  • Expert Opinion and Expert Reviews are now on facebook!

    December 18, 2013
    The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
  • Editor’s pick – new hope in the fight against prostate cancer?

    December 17, 2013
    Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has chosen this exciting topic on: Chemotherapeutic inhibitors in the treatment of prostate cancer by Dou QP et al, as the pick of the month for the January 2022 issue.
  • This month in Expert Opinion…..

    December 13, 2013

    Five articles from the Expert Opinion Series are within the top 100 most accessed articles from the Informa healthcare journal portfolio in November 2013

  • Editor’s pick – what are the new pharmacotherapy options for endometrial cancer?

    November 29, 2013
    Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has picked the review article: An update on the pharmacotherapy for endometrial cancer by Scambia et al, as the highlight of the month for the December issues.
  • Oncology is the theme for November in EOP!

    November 5, 2013
    All reviews in the November issue focus on oncology – check them out here..
  • This Week in Expert Opinion

    October 22, 2013
    This Week in the Expert Opinion journals, we look into new and not-so-new therapies for cancer, the pharmacokinetics of a common contraceptive, and wonder what special considerations are needed for clinical trials of orphan drugs. Find out more here…
  • Editor’s pick – how beneficial is canrenone in patients with metabolic syndrome?

    October 15, 2013
    Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has picked the original research: Effects of canrenone in patients with metabolic syndrome by Derosa et al, as the November issue’s editorial highlight.
  • Editor’s pick for October 2013

    October 1, 2013
    This month the Editor highlights the drug evaluation article on pimavanserin: a novel agent, for a novel indication with a novel mechanism of action!
  • Newly launched first-in-class drug for treating Chronic Myeloid Leukemia!

    August 28, 2013
    Introducing omacetaxine mepesuccinate. This semisynthetic formulation of a natural alkaloid with a novel mechanism of action, was granted accelerated approval by the FDA in October 2012, for subcutaneous use in adult CML patients, who are resistant to at least two tyrosine kinase inhibitors.
  • Editor’s pick for September 2013

    August 20, 2013
    This month’s Editor’s pick focuses on the very interesting topic regarding the use of antiretroviral agents in pre-exposure prophylaxis, and how this novel biomedical intervention can prevent the transmission of HIV among high-risk populations.
  • First-in-Class Drugs – pioneers with great potential!

    August 16, 2013
    The FDA defines a First-in-Class drug as one which uses a new and unique mechanism of action for treating a medical condition. This is a concept that immediately makes you think of words like ‘innovation’, ‘novelty’, ‘potential’, ‘pioneering’ and ‘cutting-edge’ – all things that most pharmaceutical companies look for when considering areas of R&D to pursue and invest in. While they have the potential to boost the company’s pipeline and its profit, First-in-Class drugs also come with much greater risk and are definitely not guaranteed to succeed.
  • Editor’s pick for August 2013

    July 18, 2013
    August’s pick of the month focuses on the most powerful triptan available for acute migraine: sumatriptan.
  • European patent for Pfizer’s Viagra expires – 21st June 2013

    June 24, 2013

    European patent for Pfizer’s Viagra expires – 21st June 2013

    Despite extending the patent protection on Viagra (sildenafil) in the US until 2020, Pfizer now has to face the effects of patent expiration in the UK and other countries in Europe. 

  • Editor’s pick for July 2013

    June 13, 2013
    July’s pick of the month is a very interesting drug evaluation paper written by Ballantyne and colleagues, on the role of icosapent ethyl for the treatment of hypertriglyceridemia.
  • Editor’s pick for June 2013

    May 30, 2013
    June’s pick of the month is an excellent drug evaluation paper by Aggarwal and Showkathali, who evaluate the pharmacology, efficacy and safety of rosuvastatin, as well as statin use in acute coronary syndromes.
  • Protein kinase inhibitors: small molecules making a big impact in this special issue of EOID

    May 22, 2013
    Expert Opinion on Investigational Drugs would like to present a special issue dedicated to protein kinase inhibitors. These small molecules have potential to be active therapies in a wide variety of indications, from oncology through to neurology and beyond. Along with Guest Editor Tomi Sawyer, we explore some of the interesting drugs which fall into this class in this special issue of EOID.
  • Editor’s pick for May 2013

    April 24, 2013
    This month’s pick by the Editor is the pharmacotherapy options for cataplexy, one of the major symptoms of the sleeping disorder narcolepsy.
  • Editor’s pick for April 2013

    March 14, 2013

    In this month’s issue, Fabi and colleagues explore whether Epidermal Growth Factor Receptor (EGFR) gene copy number has any significance on lapatinib sensitivity, in HER2-positive metastatic breast cancer.

    (This article is currently early online, but will be published in April Vol 14 issue 6)

  • US Prix Galien prizes awarded to ipilimumab and telaprevir

    October 24, 2012
    Showing once again how relevant and interesting the reviews in the Expert Opinion series are, ipilimumab, winner of the best biotechnology product and telaprevir, joint winnder of best pharmaceutical agent, have recently been the subject of review articles.
  • Expert Opinion on Pharmacotherapy Editor’s Pick – September (13)

    August 29, 2012
    This month, scientists from two of the world’s leading institutions, Harvard Medical School and Cambridge University, compare three newer atypical antipsychotic drugs, in an article published in Expert Opinion on Pharmacotherapy.


  • EOP Special Issue – Atypical Antipsychotics!

    July 13, 2012
    This month’s issue of Expert Opinion on Pharmacotherapy (EOP) is a special themed issue, dedicated to atypical antipsychotics!
  • Expert Opinion on Pharmacotherapy Editor’s Pick – July (10)

    June 25, 2012
    What is known about QT prolongation and analgesic drugs? Professor Robert Raffa and co-authors address this important question in the current issue of Expert Opinion on Pharmacotherapy.
  • Editor’s Pick – June (9)

    June 22, 2012
    Hair loss is a common complaint. In this month’s issue, Dr Tosti and Dr Miteva form the University of Miami Miller School of Medicine review current and future treatment options for alopecia.

    They update the literature since the release of the first edition of this article 3 years ago. They conclude that significant research success has been achieved through the discovery of the genetic profile of alopecia areata and the PPAR-γ pathway in scarring alopecia.

  • Let’s be clear – Expert Opinion on ethical publishing

    March 27, 2012
    In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.
  • Editor’s Pick – April (6)

    March 26, 2012
    In our April issue, Dr Manzouri and colleagues from Moorfields Eye Hospital outline the corneal transplant procedure and the treatment options available in the management of transplant rejection.

  • Editor’s Pick – March 2012

    March 2, 2012
    This month, Professor Guido Grassi has written an interesting evaluation of the TALENT study for Expert Opinion on Pharmacotherapy.
  • Expert Opinion on Pharmacotherapy on DocGuide

    February 22, 2012

    This weeks DocGuide has included a popular Treatment Evaluation, which was published in the February issue of EOP!

    discusses the clinical impact of Pitavastatin in comparison to other statins on LDL-C and HDL-C.

    Click here to read how Pitavastatin performed in i) Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL): the PATROL Trial; ii) various Phase III clinical trials in Western countries; iii) The Comparison of Preventive Effect on Cardiovascular Events With Different Statins (CIRCLE) study; and iv) The Livalo Effectiveness and Safety (LIVES) Study Extension.

  • Editor’s Pick – February 2012, No. 2

    February 9, 2012
    In this months issue, the editor would like to highlight an evaluation of sorafenib for the treatment of renal cancer.
  • Expert Opinion on Pharmacotherapy on DocGuide

    February 1, 2012

    One of EOP’s recently published Drug Evaluations, “Paroxetine for the treatment of depression”, has been included in DocGuide’s most popular articles!

    Drs Gibiino and Serretti from the Institue of Psychiatry at the University of Bologna, evaluate the latest data on paroxetine and investigate its clinical efficacy and safety in different groups of patients.

    Click here to read this Drug Evaluation

  • Editor’s Pick – February 2012, No. 1

    January 17, 2012
    This months highlighted article provides a comprehensive guide for the use of Tapentadol for the treatment pain, by Dr Hartrick.
  • Editor’s Pick – January 2012

    January 16, 2012
    Our Editor’s pick this month discusses antiplatelet therapy in acute coronary syndromes, by Dr Menozzi and colleagues.

  • CMEcast Podcast Courses Receive EBAC Approval

    November 16, 2011
    Informa Healthcare’s recently launched CMEcast service announced today that its first four educational courses have received official approval from the European Board for Accreditation in Cardiology (EBAC) as EBAC Accredited Educational Programmes.
  • Targeted Media, Inc. a Time Inc. company, expands partnership with Informa Healthcare Communications

    August 31, 2011

    August 31, 2011 – New York, NY – Targeted Media, Inc., a Time Inc. company, has named Informa Healthcare Communications as their exclusive sales agent for ‘The Educated Patient’ series and pharma-sponsored magazine subscriptions in Europe. This builds upon their existing partnership in the US, where Informa Healthcare Communications provides content and creative direction for the series. Informa Healthcare Communications, a division of the global STM publisher Informa Healthcare, produces medical content tailored to both physicians and patients.